Fig. 1

Expression of miR-219 in CSF of MS patients and controls. a Percentage of CSF samples with undetected miR-219 in cohort 1. b Scatter plot of miR-219 relative expression levels in CSF of individuals with detectable miR-219 levels of cohort 1. miR-219 levels were significantly decreased in SPMS and PPMS compared to controls. Levels were normalized using the geometric mean of miR-24 and miR-16. c Percentage of CSF samples with undetected miR-219 in cohort 2. d Scatter plot of relative expression levels of miR-219 in CSF of individuals with detectable miR-219 levels of cohort 2. Mean miR-219 levels in CSF of individuals with detectable miR-219 were similar in all groups. Levels were normalized using the geometric mean of miR-24 and miR-16. e Percentage of CSF samples with undetected miR-219 in cohort 3. f Scatter plot of miR-150 relative expression levels in CSF of individuals with detectable miR-150 levels of cohort 3. miR-150 levels were significantly increased in RRMS compared to PPMS, and in relapse-onset (RRMS, SPMS) compared to progressive-onset (PPMS). Levels were normalized using miR-204 levels. Black horizontal lines = median REL values ± interquartile range. * p < 0.05, ** p < 0.01. Abbreviations: RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, CIS clinical isolated syndrome, IIH idiopathic intracranial hypertension, AD Alzheimer’s disease, NHI neurologically healthy individuals, NIND non-inflammatory neurological diseases, IND inflammatory neurological diseases